Merck’s Sacituzumab Tirumotecan Shows Positive Phase 3 Results in Endometrial Cancer

Merck (NYSE:MRK) announced positive results from the global Phase 3 TroFuse-005 trial of its antibody-drug conjugate (ADC) sacituzumab tirumotecan in patients with advanced or recurrent endometrial cancer. The study met its primary endpoints, demonstrating a statistically significant improvement in both overall survival (OS) and progression-free survival (PFS) compared to standard chemotherapy. This marks the first time an ADC has shown such benefits in this indication.

The Drug

Sacituzumab tirumotecan is an ADC designed to target a specific antigen on endometrial cancer cells, delivering a cytotoxic payload directly to the tumor. This approach aims to enhance efficacy while reducing systemic toxicity.

Trial Details

The TroFuse-005 trial enrolled patients with advanced or recurrent endometrial cancer who had progressed on prior therapies. The results showed a meaningful improvement in OS and PFS, with a manageable safety profile.

Regulatory Path

Merck plans to submit regulatory filings based on these results to the FDA, EMA, and other health authorities. If approved, sacituzumab tirumotecan could become the first ADC approved for endometrial cancer.

Competitive Landscape

The drug faces competition from immune checkpoint inhibitors and hormonal therapies, but its unique mechanism as an ADC and positive Phase 3 data position it as a potential new standard of care.

Impact on Merck

This candidate could bolster Merck's oncology pipeline, which includes Keytruda. Approval would diversify revenue streams and reduce dependence on Keytruda, addressing a key investor concern.